|
Dynavax Technologies to commence Phase I asthma studies
Equities.com Comtex News Network. Nov 02, 2012 (Datamonitor via COMTEX) — Dynavax Technologies Corporation, a biopharmaceutical company, has announced that it will advance AZD1419, a second-generation TLR-9 agonist for asthma, into Phase I clinical studies. |
View full post on asthma – Google News